Rationale and design of a randomized, double‐blind, placebo‐controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT)
Explore this paper's citation graph
Summary
Ivabradine reduces heart rate directly through inhibition of the If ionic current, which is a significant marker for mortality and morbidity in cardiovascular disease including heart failure.
- Type
- article
- Published
- 2010-01-01
- Cited by
- 98
- References
- 38
- Access
- Open access
- OpenAlex
- https://openalex.org/W2058708816
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:31424539
Keywords
Ivabradine, Heart failure, Medicine, Ejection fraction, Cardiology
References
- Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF).
- [Beta-blockers in chronic heart failure].
- &bgr;-Blockers in Chronic Heart Failure
- Long-Term Trends in First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003: A Population Study of 5.1 Million People
- Effect of chronic changes in heart rate on congestive heart failure.
- Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure ☆
- Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure.
- Adequacy of diagnosis and treatment of chronic heart failure in primary health care in Sweden
- Resting heart rate in cardiovascular disease.
- The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment.
- Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey
- Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure.
- The effect of altering heart rate on ventricular function in patients with heart failure treated with beta-blockers.
- Long-Term Heart Rate Reduction Induced by the Selective If Current Inhibitor Ivabradine Improves Left Ventricular Function and Intrinsic Myocardial Structure in Congestive Heart Failure
- Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD).
- Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial
- The myocardium in congestive heart failure.
- EuroQol: the current state of play.
- Heart rate reduction--a mechanism of benefit?
- Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure).
Cited by
- I(f) inhibition in cardiovascular diseases.
- Akute und chronische Herzinsuffizienz im Spiegel der neuen ESC-Leitlinie
- Eficacia de la ivabradina en el tratamiento de la insuficiencia cardiaca
- Rate Control with Ivabradine
- Impacto do uso rápido dos betabloqueadores sobre a mortalidade e remodelamento ventricular na insuficiência cardíaca avançada
- Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT
- Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
- Ivabradine as adjuvant treatment for chronic heart failure
- The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT
- Repeated heart rate measurement and cardiovascular outcomes in left ventricular systolic dysfunction.
- Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population
- Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial
- Ivabradine
- Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure
- Clinical trials update from the European Society of Cardiology Meeting 2010: SHIFT, PEARL‐HF, STAR‐heart, and HEBE‐III
- Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure
- Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study
- Diastolic dysfunction and heart failure with a preserved ejection fraction: Relevance in critical illness and anaesthesia.
- Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients.
- Management of patients with refractory angina: Canadian Cardiovascular Society/Canadian Pain Society joint guidelines.
Related papers
- Advances in Using Ivabradine in Cardiovascular Disease
- Clinical Efficacy of Ivabradine
- Characterization of the Heart Rate-Lowering Action of Ivabradine, a Selective If Current Inhibitor
- Ivabradine, A Heart Rate Lowering Drug: A Clinical Investigation
- Why do I use ivabradine in my patients?
- Clinical Results of If Current Inhibition by Ivabradine
- Limited role and benefit of ivabradine in the treatment of angina and heart failure with reduced ejection fraction
- The Efficacy of Ivabradine Alone, Metoprolol Alone and Combination of Ivabradine and Metoprolol in Reducing Heart Rate Among Patients Undergoing Computed Tomography Coronary Angiography
- Effect of Graded Heart Rate Reduction with Ivabradine on Myocardial Oxygen Consumption and Diastolic Time in Exercising Dogs
- ROLE OF HEART RATE REDUCTION WITH IVABRADINE IN LEFT VENTRICULAR FAILURE